At NASMAC, our mission is to address the growing challenge of treating non communicable chronic diseases in Saudi Arabia through innovative, high quality, and affordable pharmaceutical solutions. For the first time in the country, we are introducing treatments specifically designed to manage chronic conditions such as diabetes, cardiovascular diseases, and respiratory disorders.
By combining global expertise with cutting-edge manufacturing, we aim to drive self-reliance and contribute to the long-term development of Saudi Arabia’s healthcare system. While treating non-communicable chronic diseases and strengthening the foundation of patient-centric care.
At NASMAC, excellence, affordability, and meaningful impact are at the core of everything we do.
Zahran Holding’s extensive industry expertise and scale provide a strong foundation for NASAQ Pharma, focused on addressing Saudi Arabia’s pharmaceutical needs.
NASMAC drawing on Macleods Pharmaceutical Ltd’s global manufacturing and Resource and Development capabilities, is committed to delivering affordable and innovative healthcare solutions, perfectly aligned with Saudi Arabia’s evolving healthcare objectives.
Behind every successful organization lies a team of passionate and experienced leaders and NASMAC is no exception.
The company’s management team brings over 40 years of combined experience in the Saudi pharmaceutical market. This expertise is not only theoretical but deeply practical, shaped by decades of navigating and overcoming the unique challenges of the Kingdom’s healthcare landscape.
NASMAC’s leadership is perfectly positioned to drive innovation, ensure operational excellence, and navigate the complexities of Saudi Arabia’s evolving healthcare system.
This visionary foundation is further strengthened by NASMAC’s pre-operational presence in NUPCO tenders. Leveraging Macleods’ extensive portfolio, NASMAC has already demonstrated its capability to compete effectively in government contracts, positioning itself not as a newcomer, but as a rising force committed to reshaping the future of Saudi Arabia’s pharmaceutical industry.